Efeect Of High Rosuvastatin On Lp-PLA2, APN And HsCRP Level In Patients With ACS After PCI

[Objective] To investigate the effect of high dose of rosuvastatin on serum lipoprotein-associated phospholipase A2(Lp-PLA2), high-sensitive C-reactive protein (hsCRP) and adiponectin (APN) in patients with ACS after percutaneous coronary intervention (PCI).[Methods] This study included120patients of ACS with PCI, who were evenly randomized to atorvastatin treatment group (under normal therapy,20mg/d atorvastatin was added, starting before PCI,), low rosuvastatin treatment group (under normal therapy,10mg/d rosuvastatin was added, starting before PCI) and high rosuvastatin treatment group (under normal therapy,20mg/d rosuvastatin was added, starting before PCI). The serum Lp-PLA2, hsCRP and APN were measured before PCI and1day, lweek as well as4week after PCI by means of Elisa. Lipids were measured before PCI.[Results] The differences of Lp-PLA2, hsCRP, APN and lipids between the three groups were not significant before PCI (P>0.05) Postoperatively for1week and4weeks, the levels of hsCRP and Lp-PLA2was decreased, however APN was increased in the low rosuvastatin treatment group compared with atorvastatin group (1W P>0.05;4W P<0.05). The levels of hsCRP and Lp-PLA2decreased more significantly, and APN elevated more significantly in the high rosuvastatin treatment group compared with atorvastatin group or low rosuvastatin group (P<0.05). The effect is concentration-dependent[Conclusion] Rosuvastatin can significantly decrease hsCRP and Lp-PLA2, elevate APN level after PCI at the early stage, and rosuvastatin had a better effect for treatment of patients with ACS compared with atorvastatin.